This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Anastrozole
Third-generation non-steroidal aromatase inhibitor — FDA-approved 1995 for postmenopausal HR+ breast cancer, off-label workhorse for…
Aliases (4)
Overview
What is Anastrozole?
Anastrozole (brand name Arimidex) is a non-steroidal aromatase inhibitor approved for hormone receptor-positive breast cancer in postmenopausal women. It is also used off-label by men on testosterone replacement therapy (TRT) to control estrogen conversion.
Key Benefits
Profoundly suppresses circulating estradiol (~80%), reduces estrogen-driven side effects on TRT (gynecomastia, water retention, mood), and is first-line adjuvant therapy for ER+ breast cancer.
Mechanism of Action
Selective, reversible, non-steroidal aromatase (CYP19A1) inhibitor. Blocks the conversion of androgens (testosterone, androstenedione) to estrogens (estradiol, estrone) in peripheral tissues, sharply lowering circulating estrogen.
Pharmacokinetics
▸Brand options2 known
StatusRx (FDA-approved 1995 for postmenopausal HR+ breast cancer adjuvant therapy and advanced metastatic disease). WADA-prohibited under S4 Hormone and Metabolic Modulators (anti-estrogenic class) — banned at all times in- and out-of-competition.
Research Protocols
Disclaimer: These are commonly discussed research protocols and not medical advice.
Peptide Interactions
Bone protection during chronic AI use is standard of care for postmenopausal breast cancer — bisphosphonates (zoledronate, alendronate) or denosumab routinel…
AI is added when TRT-induced E2 climbs symptomatically. Standard TRT-clinic stack — but the combination is *managed*, not a casual add-on.
Sometimes co-administered to maintain testicular function; the AI manages aromatization while HCG keeps Leydig cells active.
Combined ER blockade + aromatase blockade can crash tissue-level E2 to severe-deficiency phenotype. Joint pain, bone loss, lipid disruption, mood crash compo…
Redundant; never indicated. Letrozole at 2.5 mg + anastrozole 1 mg is irrational over-dosing.
Used together only in specific oncology/endocrine contexts; otherwise additive HPG suppression.
Mechanistic conflict — defeats purpose of the AI.
Hepatic burden + lipid changes compound; also alcohol independently increases aromatase activity (so high alcohol intake confounds dose-response).
Mostly clinically minor but worth flagging for completeness.
Modafinil, citicoline, NAC, magnesium, fish oil, theanine, rhodiola, curcumin, beta-alanine, creatine — no PD/PK conflict
No interaction
No PK conflict; PD non-overlapping
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Day 1PK-driven acute peak per administration. Verify dose tolerated.
- Week 1Steady-state reached for most daily-dosed pharma.
- Week 2-4Therapeutic effect established; titration window if needed.
- Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
Side Effects & Safety 16
Side Effects
- 1Arthralgia / joint pain / stiffness ~30-40% (signature side effect — knees, hands, wrists, hips most common)
- 2Hot flushes / vasomotor symptoms ~30%
- 3Fatigue / asthenia ~15-20%
- 4Headache ~10-15%
- 5Nausea / GI upset ~10-15%
- 6Bone density loss / osteoporosis progression — silent, ~2-7% BMD loss over 5 years of continuous use vs. tamoxifen
- 7Mood changes (irritability, low mood) ~10-15%
- 8Vaginal dryness, atrophy, dyspareunia (women)
- 9Sleep disturbance
- 10Carpal tunnel-like symptoms (related to fluid/joint changes)
- 11Hair thinning (mechanism unclear)
- 12Hypercholesterolemia / LDL elevation ~5-10% (less than older AIs but real)
- 13Peripheral edema ~5%
- 14Decreased libido (men, off-label) — related to E2 crash, dose-dependent
- 15Erectile dysfunction (men, off-label) — E2-crash mediated
- 16Depression / anxiety worsening (men, off-label) — E2 has cognitive/mood effects in males
When to Stop
- Severe hepatotoxicity — rare; LFT monitoring at baseline + during use recommended for chronic dosing
- Stevens-Johnson syndrome / severe skin reactions — extremely rare
- Severe allergic reactions / angioedema — rare
- Cardiovascular events — slight increase in ischemic events vs. tamoxifen in postmenopausal women (ATAC), mechanism unclear (estrogen has cardioprotective effects in women that are blunted by AI)
- Pathologic fractures (silent osteoporosis → wrist, hip, spine fractures) — particularly in long-term users without bone surveillance
- Crashing E2 syndrome (men, off-label): characteristic constellation of joint pain + libido loss + mood crash + lipid disruption + bone density loss — under-recognized iatrogenic injury in TRT/AAS communities
- Exacerbation of pre-existing cardiac disease — modest risk
- First 4-6 weeks: Watch for E2 crash signs — joint pain, libido drop, mood change. Bloodwork at 4 weeks.
- First 3 months: Recheck E2 + lipids + LFTs.
- 6 months+: Reassess continued need; if TRT-adjunct, often dose can be reduced as TRT stabilizes.
- 12 months+: DEXA if chronic use anticipated; bone density surveillance.
- Anytime: severe joint pain, sudden libido collapse, depressive mood crash → hold drug, recheck E2
- MMA training load: Bone density is *load-bearing* protection against stress fractures; AI-induced bone loss in a combat athlete with daily impact = elevated stress fracture risk that compounds over months
- Daily training cognitive demand: Mood/cognitive blunting from low E2 would directly impair business + training performance — opposite of the goal of nootropic stack
- Libido and recovery: E2 in young men supports libido and contributes to anabolic recovery signaling; AI-induced crash would impair both
- Joint health for grappling/striking: Anastrozole-induced arthralgia in a sport that demands joint health = direct sport-performance harm
- No upside to balance these risks: a user in this archetype has no high-E2 phenotype to correct
- Net: zero indication, real and multiple harms — clear NOT-RELEVANT
References
ATAC trial — Cuzick et al. 2010 (Lancet Oncology)
70257-6/fulltext) — pivotal postmenopausal HR+ breast cancer trial
View StudyMA.27 trial — Goss et al. 2013 (J Clin Oncol)
anastrozole vs. exemestane comparator
View StudyMauras et al. 2004 — Pharmacokinetics and dose-finding of anastrozole in adolescent boys (J Clin Endocrinol Metab)
pediatric off-label PK
View StudyPlourde et al. 2004 — Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial (J Clin Endocrinol Metab)
null result for adolescent gyno
View StudyLeder et al. 2004 — Effects of aromatase inhibition in elderly men with low or borderline-low serum testosterone levels (J Clin Endocrinol Metab)
male hypogonadism off-label
View StudyBurnett-Bowie et al. 2009 — Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone (J Clin Endocrinol Metab)
bone density loss in male AI users
View StudyTan & Pu 2014 — Anastrozole-induced suppression of estradiol and TRT-adjunct (case series)
TRT-adjunct context
View StudyMitwally & Casper 2004 — Aromatase inhibitors for ovulation induction (J Soc Gynecol Investig)
female fertility off-label
View StudyBuzdar 2003 — Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors (Clin Cancer Res)
AI class PK review
View StudyRiepe et al. 2008 — Aromatase inhibitors in pediatric endocrinology (Horm Res)
pediatric AI review
View StudyDias et al. 2016 — Anastrozole for E2 management in TRT (case series)
male TRT context
View StudyUSADA / WADA Prohibited List 2025-2026 (S4 Hormone and Metabolic Modulators)
anti-doping reference
View StudyFinkelstein et al. 2013 — Gonadal steroids and body composition, strength, and sexual function in men (NEJM)
landmark study showing E2's independent role in male physiology, including the sexual function and body composition signals that AI use disrupts
View StudyRochira et al. 2015 — Estrogens, male reproduction and beyond (Endotext)
comprehensive review of estrogen's roles in male physiology
View StudyRussell & Grossmann 2019 — Estradiol as a male hormone (Eur J Endocrinol)
male estrogen physiology, why crashing E2 is harmful
View StudyInhouse Pharmacy anastrozole listing
example Indian pharmacy generic source
View StudyDefy Medical TRT protocols documentation
TRT-clinic context for off-label dosing
View StudyBodybuilding.com / r/Steroids anastrozole community threads
community off-label practice context (not authoritative)
View StudySmith et al. 2008 — Estrogens and the skeleton in men (Curr Osteoporos Rep)
bone biology rationale for why low E2 in men damages BMD
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.